WaveMan
WaveMan · Company
ERAS · Erasca, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ERAS Erasca (ERAS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001761918
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
165
13F, latest reported quarter

What the filings say about ERAS

Planned sales (Form 144), 90 days
$407.9K
3 notices

Erasca insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Erasca, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-29.

Insider
Filed
Shares
Value
Since filing
Garner Ebun
Chief Legal Officer
SELL
2026-04-03 SECtraded 2026-04-01
80,000
$1.3M
-11.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Jan 7, 2026.
  • The trade is 319.0% of the 25,076 shares held after it.
  • 1 other insider sold within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Garner Ebun sold about $1.3M of ERAS on Apr 1, 2026, the largest insider sale at the company since 2021; 1 other insider sold within 30 days and 165 funds added in the latest 13F quarter.
Morris Shannon
Chief Medical Officer
SELL
2026-03-06 SECtraded 2026-03-04
20,000
$300.8K
-3.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 1 other insider sold within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Morris Shannon sold about $300.8K of ERAS on Mar 4, 2026; 1 other insider sold within 30 days and 165 funds added in the latest 13F quarter.
Garner Ebun
General Counsel & Corp. Sec.
SELL
2026-01-08 SECtraded 2026-01-07
120,000
$670.8K
+125.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 20, 2021.
  • The trade is 478.5% of the 25,076 shares held after it.
  • No other insider sold within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel & Corp. Sec. Garner Ebun sold about $670.8K of ERAS on Jan 7, 2026, the largest insider sale at the company since 2021; 165 funds added in the latest 13F quarter.
Casdin Alexander W.
Director
BUY
2024-05-22 SECtraded 2024-05-21
80,000
$181.6K
+487.6%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 4, 2023.
  • +3.5% median (+3.4% mean) 90-day return after 3 previous buys.
  • The trade is 13.9% of the 573,974 shares held after it.
  • No other insider bought within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Casdin Alexander W. bought about $181.6K of ERAS on May 21, 2024; 165 funds added in the latest 13F quarter.
Start Valerie Denise Harding
Director
BUY
2023-12-08 SECtraded 2023-12-06
10,000
$18.5K
+727.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 21, 2022.
  • -18.6% median (-18.6% mean) 90-day return after 2 previous buys.
  • The trade is 50.0% of the 20,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 165 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Start Valerie Denise Harding bought about $18.5K of ERAS on Dec 6, 2023; 2 other insiders bought within 30 days and 165 funds added in the latest 13F quarter.
25 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 20 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
165 funds bought in last quarter
more than 85% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
14.5% of the float short (float per yahoo 2026-10-27) · 6.3 days to cover · settled 2026-10-15
more than 74% of Pharma & Biotech
What changed in the last 30 days
Oct 15Foundation Erasca Foundation filed to sell $122.4K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ERAS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+539.5%12M
-8%+276%+560%+844%2025-102025-122026-022026-042026-062026-082026-10 2026-04-01 · Garner Ebun sold $1.3M2026-01-07 · Garner Ebun sold $670.8K2026-03-04 · Morris Shannon sold $300.8K2026-10-15 · Erasca Foundation filed to sell $122.4K2026-09-15 · Erasca Foundation filed to sell $133.1K2026-08-17 · Erasca Foundation filed to sell $152.4K2026-07-21 · Erasca Foundation filed to sell $157.6K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ERAS: institutional holders (13F)

13F holdings, latest reported quarter
Frazier Life Sciences Management, L.P.
24,975,188 sh
$457.5M
BlackRock, Inc.
21,154,146 sh
$387.5M
RTW INVESTMENTS, LP
17,946,754 sh
$328.8M
Venrock Adviser, LLC
17,891,812 sh
$327.8M
STATE STREET CORP
12,184,555 sh
$223.2M

Congress trades in ERAS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ERAS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Erasca Foundation
Filed 2026-10-15
$122.4K
Erasca Foundation
Filed 2026-09-15
$133.1K
Erasca Foundation
Filed 2026-08-17
$152.4K
Erasca Foundation
Filed 2026-07-21
$157.6K

ERAS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Dorsey Wright Healthcare Momentum ETF
$6.9M position · as of 2026-07-31
2.9%
ALGER SMALL CAP FOCUS FUND
$17.3M position · as of 2026-07-31
2.0%
Victory Pioneer Select Mid Cap Growth VCT Portfolio
$1.7M position · as of 2026-06-30
1.4%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$136.4M position · as of 2026-06-30
1.3%
PROFUND VP BIOTECHNOLOGY
$603.3K position · as of 2026-06-30
1.2%
ALGER SMALL CAP GROWTH FUND
$2.4M position · as of 2026-07-31
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
5
Phase 1
3 active
1
Phase 3
1 active
2
Multi-phase
0 active
What changed recently
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic So
2026-09-17 · Active Not Recruiting → Completed
Phase 1
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Adva
2026-09-17 · Active Not Recruiting → Completed
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 165 funds added last quarter, $407.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ERAS financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$98.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-78.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-65.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-73.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-1.8%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$140.9M-$179.6M-$141.5M-$247.4M
Net income-$124.5M-$161.7M-$125.0M-$242.8M
EPS (diluted)-0.44-0.69-0.83-1.99
Operating cash flow-$95.5M-$109.4M-$101.2M-$103.3M
Cash$73.8M$67.7M$93.1M$284.2M
SEC XBRL, fiscal years, as known on 2026-10-29

ERAS Stock Sonar score 3/7 axes

Find similar shapesCompare

ERAS ranks highest on institutional and government (85th percentile) and profitability (37th), and lowest on risk and compliance (26th), among Pharma & Biotech peers.

Profitability
37
Inputs
  • Return on equity-78.2% · 40 pct, sector of 545
  • Return on assets-65.2% · 36 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-73.9% · 35 pct, sector of 576
Institutional and government
85
Inputs
  • Funds adding, latest quarter165 · 85 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
26
Inputs
  • Short interest, % of float+14.5% · 26 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ERAS filings, in plain words

Are there planned insider sales of ERAS?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-29, covering $407.9K of stock; the latest, by Erasca Foundation, was filed 2026-10-15.

Read the full summary

Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-29, covering $407.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-29, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies